drug
(insulin degludec + liraglutide)
Marketedupdated 3mo agoby Novo Nordisk Inc
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3indications
investigational
Type 2 Diabetes
all catalysts(0)
nothing on the calendar yet
Trials studying (insulin degludec + liraglutide)
- —Regulatory Post Marketing Surveillance (rPMS) Study of Xultophy® (Insulin Degludec/Liraglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea
- phase3A Trial Investigating the Efficacy and Safety of Insulin Degludec/Liraglutide Injection in Subjects With Type 2 Diabetes
- phase1A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide in Healthy Chinese Subjects
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 28m ago
Found something off?
comments(0)
5-min edit window · permanent after that